Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase 2, multicenter, open-label, go-to-market trial to evaluate the safety and efficacy of THIO in combination with the immunotherapies pembrolizumab or atezolizumab in patients with multiple tumor types, including small cell lung cancer, liver cancer and colorectal cancer

Next Previous
Trial Profile

A second phase 2, multicenter, open-label, go-to-market trial to evaluate the safety and efficacy of THIO in combination with the immunotherapies pembrolizumab or atezolizumab in patients with multiple tumor types, including small cell lung cancer, liver cancer and colorectal cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ateganosine (Primary) ; Antineoplastics; Atezolizumab; Etoposide; Pembrolizumab; Platinum complexes
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors MAIA Biotechnology

Most Recent Events

  • 07 Jan 2025 According to a MAIA Biotechnology media release, MAIA will sponsor and fund the planned clinical trials and BeiGene will provide tislelizumab
  • 20 Feb 2023 New trial record
  • 13 Feb 2023 According to a MAIA Biotechnology media release, Part B of this study will include multiple Phase 2 pivotal arms seeking accelerated approvals.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top